The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients […] Read more
Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis […] Read more
The Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose […] Read more
Two large-scale, randomized controlled trials—the U.S. National Lung Screening Trial (NLST; n = 53,454) and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON; n = 15,792)—have demonstrated that lung cancer […] Read more
COVID-19 and Lung Cancer
+more
Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw […] Read more
Amid growing interest in validating relapse-prediction models, team links high-grade histology, even if not predominant, with worse outcomes in EGFR-mutated stage 1 NSCLC. Read more